Pfizer Starts Human Trials of Messenger RNA Flu Vaccine

Pfizer reported Monday that it had started the first human trials of a flu vaccine with messenger RNA technology, already used in its vaccine. COVID-19.

SIGHT: Delta Plus variant of the coronavirus: More contagious and resistant to vaccines?

The American biotechnology company of such a product in early July.

The Pfizer clinical trial is conducted in the United States and will evaluate the safety of a dose of the new vaccine, as well as its immunogenicity (ability to induce an immune response), in healthy people between 65 and 85 years of age.

SIGHT: COVID-19 | Patients who come to the ICU are mostly men and have more antibodies

It will include a few hundred participants, according to clinical trial details published in

Current flu vaccines use inactivated viruses, a time-consuming process. The constantly changing target strains of the virus should be chosen for the beginning of the seasonal epidemic.

SIGHT: COVID-19 | Results of the Sinopharm clinical trial conducted in Peru will be “very soon”

The efficacy of currently used vaccines is typically between 40% and 60%.

“The flexibility of messenger RNA technology and its rapid production could allow a better association with the strain (of the circulating virus), a greater reliability in the supply and ”, Pfizer noted in its statement.

The World Health Organization estimates that the flu causes between three and five million cases of serious illness and between 290,000 and 650,000 deaths each year.

In addition to the flu, Pfizer said it plans to study the use of messenger RNA technology against other respiratory viruses, as well as against genetic diseases or cancers.

• COVID-19 | Patients who come to the ICU are mostly men and have more antibodies
• COVID-19 | Results of the Sinopharm clinical trial conducted in Peru will be “very soon”
• Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
• What are “rogue” antibodies and what do they have to do with severe COVID-19?
• What will the third year of the pandemic be like ?, by Elmer Huerta
• COVID-19 | New Chinese vaccine is 79% effective against Delta variant
• COVID-19 May Look Like a Cold in the Future, AstraZeneca Developer Says
• Delta variant of COVID-19 is now predominant in Peru: five things you should know
• COVID-19 | Europe will decide in October whether to authorize Pfizer’s booster dose
• Sinopharm will be accepted to travel to the US: reasons to trust the Chinese vaccine
• COVID-19 | How close are we to the end of the pandemic?
• Who will the third dose of Pfizer reach in the US?
• COVID-19 infection may precede Guillain-Barré syndrome in rare cases
• COVID-19 | “It is a harm to public health for someone to apply more than two doses on their own”
• COVID-19 | Six billion doses of vaccines have been administered worldwide
• They find a virus very similar to that of COVID-19 in bats of Laos
• Brazil and Argentina will produce mRNA vaccines against COVID-19 for the region, PAHO announces
• Convalescent Plasma: Does This Therapy Work To Treat COVID-19 Patients?

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn